A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | MicrobiomeTrials← Back to trialsNCT07020221
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2025-06-24Est. Completion: 2028-12
Enrollment target: 616 participants Locations- Cedars-Sinai Medical Center, Los Angeles, California, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Laura & Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States
- Univ of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States
- SCRI Oncology Partners, Nashville, Tennessee, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- Huntsman Cancer Institute, Salt Lake City, Utah, United States
- University of Virginia, Charlottesville, Virginia, United States
- Virginia Cancer Specialists, Fairfax, Virginia, United States
- Virginia Mason Medical Center, Seattle, Washington, United States
- Macquarie University, Sydney, New South Wales, Australia
- Peninsula and Southeast Oncology, Frankston, Victoria, Australia
Other microbiome trials you might be interested in
Pancreatic Carcinoma
This study investigates how often abnormal findings from routine magnetic resonance imaging occur in people with genetic…
San Francisco, United StatesCompleted Oct 19, 2026
CancerPDAC - Pancreatic Ductal AdenocarcinomaNSCLC (Non-small Cell Lung Cancer)CRC (Colorectal Cancer)Advanced Solid Tumors
The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumor…
Orlando, United StatesEst. completion May 2029
Centre Leon Berard, Lyon, FranceCentre d'Essais Precoces en Cancerologie de Marseille (CEPCM), Marseille, FranceInstitut Curie, Paris, FranceSTART Madrid - FJD, Madrid, SpainSTART Madrid CIOCC - Hospital HM Sanchinarro, Madrid, SpainMalignant Solid TumorsOther Neoplasms Solid TumorsPediatric Solid TumorRefractory Solid TumorsSolid Tumor
Background:
Approximately 150 cases of cancer per one million per year are considered rare cancers. While all tumors or…
Bethesda, United StatesEst. completion May 31, 2028